APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAscentage Pharma Group Inc.
About this trial
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Eligibility criteria
Qualifiers
Part A: No gender limitation. Patients with histologically and/or cytologically confirmed ALK/ROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.
At least one measurable tumor lesion.
ECOG score is 0~1.
Life expectancy of ≥3 months.
Disqualifiers
Undergone major surgery or major trauma within 28 days before first dose or a diagnostic biopsy within 14 days before first dose.
Received systemic antitumor drugs, including investigational drugs.
Received radiotherapy within 14 days before first dose.
Previous treatment with FAK inhibitors.
Trial design
Treatments tested in this trial
- APG -2449
- PLD
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
1Sun Yat-sen University Cancer Center510060, GuangzhouGuangdong, China
Sponsors and collaborators
Ascentage Pharma Group Inc.
Lead sponsor
Source ClinicalTrials.gov